Sex as a predictor of response to cancer immunotherapy

Affiliations

¹ Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: jmcquade@mdanderson.org.
² Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
³ Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
⁴ Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Comment

Jennifer L McQuade et al. Lancet Oncol. 2018 Aug.

. 2018 Aug;19(8):e376.

doi: 10.1016/S1470-2045(18)30483-2.

¹ Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: jmcquade@mdanderson.org.
² Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
³ Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
⁴ Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

No abstract available

Comment in

Sex as a predictor of response to cancer immunotherapy - Authors' reply.
Conforti F, Pala L, Bagnardi V, De Pas T, Marco M, Viale G, Gelber R, Goldhirsch A. Conforti F, et al. Lancet Oncol. 2018 Aug;19(8):e380-e381. doi: 10.1016/S1470-2045(18)30535-7. Lancet Oncol. 2018. PMID: 30102230 No abstract available.

Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis.
Conforti F, Pala L, Bagnardi V, De Pas T, Martinetti M, Viale G, Gelber RD, Goldhirsch A. Conforti F, et al. Lancet Oncol. 2018 Jun;19(6):737-746. doi: 10.1016/S1470-2045(18)30261-4. Epub 2018 May 16. Lancet Oncol. 2018. PMID: 29778737